NASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $0.78 +0.00 (+0.25%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.77 -0.01 (-1.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tenaya Therapeutics Stock (NASDAQ:TNYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tenaya Therapeutics alerts:Sign Up Key Stats Today's Range$0.75▼$0.7950-Day Range$0.68▼$0.9252-Week Range$0.53▼$2.35Volume1.80 million shsAverage Volume2.38 million shsMarket Capitalization$168.18 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingModerate Buy Company Overview Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses. Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease. The company’s lead programs are advancing through preclinical and early clinical stages, with a focus on establishing proof of concept in relevant patient populations. Research collaborations and strategic partnerships support Tenaya’s efforts to accelerate development timelines and expand its scientific capabilities. Tenaya operates primarily in the United States, where it maintains its main research and manufacturing facilities. The company also engages with regulatory authorities to shape the clinical development and eventual commercialization of its therapies. Its management team combines expertise in gene therapy, cardiovascular biology and biopharmaceutical development, positioning Tenaya to tackle the complex challenges of translating novel genetic medicines into practical treatments. With a commitment to addressing unmet needs in cardiovascular health, Tenaya Therapeutics seeks to transform the treatment landscape for patients with inherited heart diseases. By integrating advanced vector engineering with a deep understanding of cardiac biology, the company strives to deliver breakthrough therapies that offer long‐lasting benefits and improved quality of life.AI Generated. May Contain Errors. Read More Tenaya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreTNYA MarketRank™: Tenaya Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 402nd out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingTenaya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTenaya Therapeutics has a consensus price target of $4.00, representing about 416.1% upside from its current price of $0.78.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tenaya Therapeutics are expected to grow in the coming year, from ($0.42) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tenaya Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.78% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 7.42.Change versus previous monthShort interest in Tenaya Therapeutics has recently decreased by 5.01%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.94 News SentimentTenaya Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tenaya Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows9 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,317.00 in company stock.Percentage Held by Insiders2.53% of the stock of Tenaya Therapeutics is held by insiders.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNYA Stock News HeadlinesTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $4.00 Consensus PT from AnalystsJuly 22 at 3:45 AM | americanbankingnews.comTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)July 14, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Tenaya Names Eric Hyllengren as CFOJune 29, 2026 | marketwatch.comTenaya Therapeutics Appoints Eric Hyllengren as Chief Financial OfficerJune 29, 2026 | globenewswire.comTenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks TranscriptJune 5, 2026 | seekingalpha.comAnalysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Tenaya Therapeutics (TNYA)June 5, 2026 | theglobeandmail.comTenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac ...June 4, 2026 | finance.yahoo.comSee More Headlines TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $0.7115 on January 1st, 2026. Since then, TNYA shares have increased by 8.9% and is now trading at $0.7750. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) issued its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). The business earned $0.23 million during the quarter, compared to analyst estimates of $7.50 million. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $180 million in an IPO on Thursday, July 29th 2021. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Tenaya Therapeutics' top institutional shareholders include Mirador Capital Partners LP (0.42%). Insiders that own company stock include Faraz Ali, Timothy Hoey, Whittemore Tingley, Tomohiro Higa, Chihiro Saito and Group Gp Lp Column III. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenaya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/06/2026Today7/25/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 TNYA's financial health is in the Yellow zone, according to TradeSmith. TNYA has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNYA CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees110Year Founded2016Price Target and Rating Average Price Target for Tenaya Therapeutics$4.00 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+416.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.60 million Net MarginsN/A Pretax Margin-36,891.11% Return on Equity-80.56% Return on Assets-65.21% Debt Debt-to-Equity RatioN/A Current Ratio5.75 Quick Ratio5.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.36Miscellaneous Outstanding Shares217,000,000Free Float211,509,000Market Cap$168.18 million OptionableOptionable Beta2.83 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TNYA) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThey’re still buying the wrong AI stocksTesla and Alphabet just tumbled, and many investors concluded AI is over. It isn't - the easy AI trade may be....The Oxford Club | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
